Record High GLP-1 Use; Intense Interval Exercise; Endometriosis and Androgens

Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it

Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34% in 2024, the survey said.